Vikram Purohit
Stock Analyst at Morgan Stanley
(3.38)
Main Sectors:
32 Stocks
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ABSI Absci | Maintains: Overweight | 7 6 | 3.38 | 74.26% | 3 | Aug 18, 2025 | |
HALO Halozyme Therapeutic... | Maintains: Overweight | 75 80 | 68.98 | 15.98% | 10 | Aug 18, 2025 | |
RXRX Recursion Pharmaceut... | Assumes: Equal-Weight | 5 | 5.49 | -8.93% | 4 | Jul 3, 2025 | |
ASND Ascendis Pharma | Upgrades: Overweight | 180 250 | 204.05 | 22.52% | 19 | May 5, 2025 | |
INCY Incyte | Maintains: Equal-Weight | 69 65 | 86.85 | -25.16% | 24 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 125 190 | 120.3 | 57.94% | 19 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 35 | 21.76 | 60.85% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 6 9 | 4.64 | 93.97% | 9 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 31 31 | 33.56 | -7.63% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 6 | n/a | n/a | 7 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 7 | n/a | n/a | 16 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 15 16 | 83.92 | -80.93% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 6.43 | 366.56% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 22 | n/a | n/a | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 10 | 19.92 | -49.8% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 46 6 | 3.6 | 66.67% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 43 42 | 10.43 | 302.68% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 10 | n/a | n/a | 4 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 23 | n/a | n/a | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 60 30 | n/a | n/a | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 3 | n/a | n/a | 2 | Jan 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 38 41 | 57.9 | -29.19% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 120 40 | 18.1 | 120.99% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 13 | 2.75 | 372.73% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 39 38 | 20.59 | 84.56% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 24 20 | 13.07 | 53.02% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 11 10 | 14.41 | -30.6% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 7 | n/a | n/a | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 2.11 | 942.65% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 25 60 | n/a | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 40 20 | 12.9 | 55.04% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | n/a | n/a | n/a | 2 | Mar 3, 2020 |